Three-times-daily radiotherapy with induction chemotherapy in locally advanced non-small cell lung cancer: Feasibility and toxicity study

Strahlentherapie und Onkologie

Volumn 181, Issue 6, 2005, Pages 363-371

  Catalano, Gianpiero ^a   Jereczek Fossa, Barbara Alicija ^a   De Pas, Tommaso ^a   Leon, Maria Elena ^a   Cattani, Frederica ^a   Spaggiari, Lorenzo ^a   Veronesi, Giulia ^a   De Braud, Filippo ^a   Orecchia, Roberto ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute toxicity; Esophagitis; Hyperfractionated radiotherapy; Induction chemotherapy; Lung cancer; Three times daily radiotherapy

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DOSIMETRY; ESOPHAGITIS; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PNEUMONIA; POSTOPERATIVE PERIOD;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ESOPHAGUS; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 21044458298     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1332-8     Document Type: Article

References (39)

1. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-9.
2. Bauman M. Accelerated radiation therapy in non-small cell lung cancer. Radiother Oncol 1999;52:97-9.
3. Bollmann A, Blakenburg T, Haerting J, et al. Survival of patients in clinical stages I-IIIb of non-small-cell lung cancer treated with radiation therapy alone. Results of a population-based study in Southern Saxony-Anhalt. Strahlenther Onkol 2004;180:488-96.
4. Byhardt RW, Scott C, Sause WT, et al. Response, toxicity, failure patterns and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998;42:469-78.
5. Cardenal F, Paz López-Cabrerizo M, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17:12-8.
6. Choi H, La Porte K, Knill-Selby E, et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999;9:90-6.
7. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997;15:712-22.
8. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with > 69.6 Gy in favorable patients with RTOG stage III non small cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-55.
9. Crinò L, Conte P, De Marinis F, et al. A randomized trial of gemcitabine cisplatin versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase III study. J Clin Oncol 1999;17:3522-30.
10. De Pas T, Catalano G, Pastorino U, et al. Very low acute toxicity of three fractions per day accelerated radiotherapy given after induction chemotherapy and surgery in stage III non-small cell lung cancer. Lung Cancer 2000;30:149-50.
11. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-4.
12. Dillman RO, Seagren S, Propert K, et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990;323:940-5.
13. Fowler JF. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.
14. Hof H, Herfarth KK, Munter M, et al. The use of multislice CT for the determination of respiratory lung tumor movement in stereotactic single-dose irradiation. Strahlenther Onkol 2003;179:542-7.
15. International Commission on Radiation Units and Measurements (ICRLI) Report 50. Prescribing, recording and reporting photon beam therapy. Bethesda: ICRLI, 1993.
16. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995;13:452-8.
17. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-70.
18. Komaki R, Scott C, Sause WT, et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997;39:537-44.
19. Kumar P, Herndon J, Langer M, et al. Patterns of disease failure after trimodality therapy of non-small-cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer 1996;77:2393-9.
20. Langer CJ. Concurrent chemoradiation using paclitaxel and carboplatin in locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999;9:108-16.
21. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non resectable non small cell lung cancer. Lung Cancer 1994;10: S239-44.
22. Lee JS, Scott C, Komaki R, et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06. J Clin Oncol 1996;14:1055-64.
23. Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999;45:97-103.
24. Metha M, et al. Phase II trials of hyperfractionated accelerated radiation therapy for nonresectable non-small cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 1998;16:3518-23.
25. Non-Small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;331: 899-909.
26. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-9.
27. Rinaldi M, Crinò L, Scagliotti G, et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 2000;1:1295-300.
28. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. Lancet 1997;350:161-5.
29. Saunders M, Dische S, Barrett A, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomized multicentre trial. Radiother Oncol 1999;52:137-48.
30. Saunders M, Rojas A, Lyn BE, et al. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2002;14:352-60.
31. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000;117:358-64.
32. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non small cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
33. Semrau S, Bier A, Thierbach U, et al. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Strahlenther Onkol 2003;179:823-31.
34. Shibamoto Y, Jeremic B, Acimovic L, et al. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2001;50:295-300.
35. Singh AK, Lockett MA, Bradley JD. Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003;55:337-41.
36. Van Zandwijk N, Smit EF, Kramer GWP, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000;18:2658-64.
37. Werner-Wasik M, Pequignot E, Leeper D, et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. Int J Radiat Oncol Biol Phys 2000;48:689-96.
38. Willner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 2003;179:548-56.
39. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.